| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23ec872637dd23aee3ea8f3de7258301 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06Q50-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2016-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b56367177cd7bd51601857e457386668
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b970a061ea3e91624972d6bc1634b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_913946f9eedc82555c8e04923a1cdcba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dfab6e451ac3be04390c48dcf434e41 |
| publicationDate |
2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9855254-B2 |
| titleOfInvention |
Methods of treating hepatic encephalopathy |
| abstract |
The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335397-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633384-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021275507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020108051-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10314828-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10709694-B2 |
| priorityDate |
2008-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |